Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
91.00
+1.44 (1.61%)
Mar 4, 2026, 4:00 PM EST - Market closed
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Rhythm Pharmaceuticals stock have an average target of 129.43, with a low estimate of 94 and a high estimate of 176. The average target predicts an increase of 42.23% from the current stock price of 91.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $141 → $140 | Strong Buy | Maintains | $141 → $140 | +53.85% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $125 → $110 | Strong Buy | Maintains | $125 → $110 | +20.88% | Mar 2, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $145 → $136 | Buy | Maintains | $145 → $136 | +49.45% | Feb 27, 2026 |
| Citizens | Citizens | Buy Maintains $167 → $176 | Buy | Maintains | $167 → $176 | +93.41% | Feb 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $140 → $143 | Strong Buy | Maintains | $140 → $143 | +57.14% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
300.53M
from 189.76M
Increased by 58.38%
Revenue Next Year
552.83M
from 300.53M
Increased by 83.95%
EPS This Year
-2.75
from -3.11
EPS Next Year
0.43
from -2.75
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 347.0M | 709.9M | |||
| Avg | 300.5M | 552.8M | |||
| Low | 257.6M | 436.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 82.9% | 136.2% | |||
| Avg | 58.4% | 84.0% | |||
| Low | 35.8% | 45.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.08 | 2.13 | |||
| Avg | -2.75 | 0.43 | |||
| Low | -3.58 | -1.03 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.